Integra LifeSciences Holdings Corporation (IART - Free Report) recently announced that it has been chosen as a key provider for cellular-based tissue products within Healogics’ new iSupply program. Notably, the program aims at making advanced wound care products exclusively available for Healogics’ hospital partners. These products are commonly used in Wound Care Centers and other sites of care.
Notably, Integra Lifesciences will be the major provider for cellular-based tissue products like AMNIOMATRIX Amniotic Allograft Suspension, PriMatrix Dermal Repair Scaffold as well as many more for the treatment of acute and chronic complex wounds. The company will also supply Omnigraft Dermal Regeneration Matrix for treating diabetic foot ulcers along with its total contact casting system, TCC-EZ, for offloading and protection of wounds as a part of the iSupply program.
Encouragingly, Healogics is a leading wound healing expert in the United States. More than 330,000 patients received advanced wound care through a nationwide network of 700 Wound Care Centers in 2017. Furthermore, Healogics also has tie-ups with more than 300 skilled nursing facilities to care for patients suffering with chronic wounds and offers inpatient consulting at 85 partner hospitals.
Additionally, per a report by MarketsandMarkets, the Regenerative medicine market is expected to witness a CAGR of 23.6% between 2016 and 2021.
In view of this, we believe that the recent development will boost top-line contributions from the Orthopedics and Tissue Technologies segment.
Orthopedics and Tissue Technologies at a Glance
The Orthopedics and Tissue Technologies segment includes specialty metal implants for surgery of the upper and lower extremities, skin and wound repair products as well as bone grafts, nerve and tendon repair products.
The acquisition of Derma Sciences in 2017 provided the company with a relevant scale in outpatient wound care, which doubled sales force in the United States and expanded business base with advanced products such as Medihoney, weight offloading and amniotic tissue.
Integra Lifesciences’ Orthopedics and Tissue Technologies segment accounted for 34.6% of the company’s total revenues in the last reported quarter. Notably, the company recently announced plans to expand sales channel, improve focus and competitiveness as well as better align the product portfolio with clinical customers.
In the past six months, Integra Lifesciences has been consistently outperforming its industry. The stock has rallied 9.5%, against the 19.1% decline of the industry.
Zacks Rank & Key Picks
Integra Lifesciences currently carries a Zacks Rank #3 (Hold).
A few better-ranked stocks in the broader medical space are Integer Holdings Corporation (ITGR - Free Report) , Intuitive Surgical (ISRG - Free Report) and Masimo Corporation (MASI - Free Report) .
Integer Holdings’ expected long-term earnings growth rate is 15%. The stock has a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Intuitive Surgical’s long-term expected earnings growth rate is 14.7%. The stock carries a Zacks Rank of 1, currently.
Masimo’s long-term expected earnings growth rate is 14.8%. Currently, the stock holds a Zacks Rank #2.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>